Phase 3 Lung Cancer Trial, Recruiting NCT06634966 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT06634966
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have signed a consent form and are willing to follow the study plan from start to finish
  • You are between 18 and 80 years old
  • You are generally able to carry out daily activities with little or no limitation (confirm with trial site)
  • You have not had lung cancer surgery before
  • Your lung tumor has been confirmed during or after surgery to be a specific type called invasive lung adenocarcinoma (a type of lung cancer)
  • Your lung nodule appears mostly as a "ground glass" pattern on a scan (a hazy, cloud-like area rather than a solid mass)
  • The solid portion of your tumor makes up between 50% and 100% of its total size, and the overall tumor size is between 2 and 3 centimetres
  • Your cancer has not spread to nearby lymph nodes or to other parts of the body
  • Your surgeon has assessed that the tumor can be fully removed with surgery
  • You have not received chemotherapy or radiotherapy before

Who may not be able to join:

  • Your tumor's solid portion falls outside the 50–100% range, or the tumor is smaller than 2cm or larger than 3cm
  • Your surgeon does not believe the tumor can be completely removed
  • Your tumor has not been confirmed as lung adenocarcinoma through tissue or cell testing
  • You have already had surgery for lung cancer
  • You have already received radiotherapy or chemotherapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

5-year disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov